clinical trial · NCT06526819
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.·phase2·recruiting·n = 120
Solid TumorSMP3124LP
brief summary
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
started
Aug 14, 2024
primary completion
Dec 1, 2028
completion
May 1, 2029
last updated
Feb 27, 2026
detailed description
Phase 1/2, global, multicenter, open-label, first-in-human, clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of SMP-3124
official title
An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol